Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab added to commercial CAR-T for refractory or resistant DLBCL with stable or progressive disease at lymphodepletion
MOH_2022-03-31_010704Phase 2Not yet recruiting
- Sponsor
- פרופ' רון רם
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab and autologous anti-CD19 CAR-T cells in diffuse large B-cell lymphoma (DLBCL), sponsored by פרופ' רון רם. Planned start Mar 2022; status: not yet recruiting.
02
Drugs
nivolumabautologous anti-CD19 CAR-T cells
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on MOH_2022-03-31_010704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-03-31_010704.